Effect of imatinib on bone metabolism in patients with chronic myelogenous leukemia or gastrointestinal stromal tumors.
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2013
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours
- Focus Pharmacodynamics
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 30 Jan 2012 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.